Daré Bioscience 경영진
경영진 기준 점검 4/4
Daré Bioscience CEO는 Sabrina Johnson, May2015 에 임명되었습니다 의 임기는 8.83 년입니다. 총 연간 보상은 $801.08K, 64.8% 급여 및 35.2% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 $227.69K 가치에 해당하는 회사 주식의 0.55% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 9.5 년과 8.8 년입니다.
핵심 정보
Sabrina Johnson
최고경영자
US$801.1k
총 보수
| CEO 급여 비율 | 64.75% |
| CEO 재임 기간 | 11yrs |
| CEO 지분 보유율 | 0.6% |
| 경영진 평균 재임 기간 | 9.5yrs |
| 이사회 평균 재임 기간 | 8.8yrs |
최근 경영진 업데이트
Recent updates
새로운 내러티브 • Apr 03
Women’s Health Pipeline Risks Will Persist Yet Long Term Potential Will Eventually Emerge
Catalysts About Daré Bioscience Daré Bioscience develops women’s health products across sexual health, contraception, menopause, vaginal health and infectious disease, with a focus on differentiated formulations built around known compounds. What are the underlying business or industry changes driving this perspective?
새로운 내러티브 • Mar 20
Women’s Health Pipeline And Dual 503B Pathway Will Transform Long Term Earnings Potential
Catalysts About Daré Bioscience Daré Bioscience focuses on developing and commercializing women’s health products across sexual health, contraception and menopause. What are the underlying business or industry changes driving this perspective?
새로운 내러티브 • Mar 05
Women’s Health Platform And 503B Launches Will Reshape Long-Term Outlook
Catalysts About Daré Bioscience Daré Bioscience is a women's health company focused on developing and commercializing clinically supported products across sexual health, contraception, menopause and vaginal health. What are the underlying business or industry changes driving this perspective?분석 기사 • Nov 07
We're A Little Worried About Daré Bioscience's (NASDAQ:DARE) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...분석 기사 • Jul 21
We Think Daré Bioscience (NASDAQ:DARE) Needs To Drive Business Growth Carefully
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...분석 기사 • Mar 12
Is Daré Bioscience (NASDAQ:DARE) In A Good Position To Invest In Growth?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Seeking Alpha • Oct 17
Daré rises on positive data from early-to-mid-stage trial of intravaginal ring to treat menopause symptoms
Daré Bioscience (NASDAQ:DARE) is trading 6.5% higher after the company announced positive data from its Phase 1/2 clinical trial of investigational intravaginal ring, DARE-HRT1, to treat the vasomotor symptoms and genitourinary syndrome associated with menopause. The drug is designed to deliver bio-identical 17β-estradiol and bio-identical progesterone continuously over a 28-day period as part of a hormone therapy regimen. The topline data from the study showed improvement in both vasomotor symptoms as well as vaginal symptoms of menopause. The primary objective or the main goal of the study was to demonstrate the safety, tolerability, and pharmacokinetics (PK) of two different dose combinations over 12 weeks of use. The company said the levels of estradiol released from both the lower and higher dose formulation of DARE-HRT1 evaluated in the study achieved statistically significant improvement. Menopausal symptoms, including hot flashes and night sweats, were reduced compared with baseline in both DARE-HRT1 dose groups. The topline PK data from the study will be available later in Q4.Seeking Alpha • Oct 10
Daré Bioscience rises as company submits application to begin trial of non-hormonal contraceptive
Daré Bioscience (NASDAQ:DARE) is trading 5.3% higher after the U.S. Food and Drug Administration approved its investigational device exemption (IDE) application to conduct an efficacy study of investigational hormone-free monthly intravaginal contraceptive, Ovaprene. The IDE approval will mean the FDA determined that the company provided sufficient data to support the initiation and conduct of the study. The submission included the results of the postcoital test clinical study of Ovaprene, in which the therapy prevented sperm from entering the cervical canal across all women and all cycles evaluated. The company is targeting mid-year 2023 to begin study recruitment.Seeking Alpha • Aug 29
Dare Bioscience reports positive progress for cream for female sexual arousal disorder
Dare Bioscience (NASDAQ:DARE) said that based on an interim analysis of phase 2b data for its sildenafil cream for female sexual arousal disorder, enrollment in the study will complete in Q4. Total enrollment will be 150 women. The company anticipates a top-line data announcement in Q2 2023. Sildenafil is the active ingredient in Viagra, a pill approved for erectile dysfunction. Dare (DARE) noted that its sildenafil cream is designed to be applied to the vaginal tissue just prior to intercourse to increase blood flow directly to the tissue. Seeking Alpha Quant Rating views Dare (DARE) as a hold with high marks for growth and revisions.Seeking Alpha • Jun 30
Daré Bioscience signs agreement with Organon for bacterial vaginosis therapy
Women health firm Daré Bioscience (NASDAQ:DARE) announced an exclusive license agreement with clinical-stage biopharma firm Organon (NYSE:OGN) to commercialize Xaciato, DARE's treatment of bacterial vaginosis in patients 12 years of age and older. Under the agreement, Daré will receive a $10M upfront payment from Organon and is eligible to receive potential milestone payments of up to $182.5M and tiered double-digit royalties based on net sales. Xaciato will be commercially available in the U.S. in Q4, DARE said. The companies entered into the agreement on March 31.분석 기사 • Apr 02
Will Daré Bioscience (NASDAQ:DARE) Spend Its Cash Wisely?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Seeking Alpha • Jan 07
Diving Back Into Daré Bioscience Again
Today, we revisit women's health concern Daré Bioscience for the first time in nearly a year. This small cap concern just received its first FDA approval and is advancing other candidates in its pipeline. A full investment analysis follows in the paragraphs below.분석 기사 • Nov 26
We Think Daré Bioscience (NASDAQ:DARE) Needs To Drive Business Growth Carefully
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...분석 기사 • Dec 22
Why Daré Bioscience, Inc. (NASDAQ:DARE) Could Be Worth Watching
While Daré Bioscience, Inc. ( NASDAQ:DARE ) might not be the most widely known stock at the moment, it led the NASDAQCM...CEO 보수 분석
| 날짜 | 총 보수 | 급여 | 회사 수익 |
|---|---|---|---|
| Dec 31 2025 | US$801k | US$519k | -US$13m |
| Sep 30 2025 | n/a | n/a | -US$17m |
| Jun 30 2025 | n/a | n/a | -US$19m |
| Mar 31 2025 | n/a | n/a | -US$2m |
| Dec 31 2024 | US$898k | US$495k | -US$4m |
| Sep 30 2024 | n/a | n/a | -US$4m |
| Jun 30 2024 | n/a | n/a | -US$7m |
| Mar 31 2024 | n/a | n/a | -US$29m |
| Dec 31 2023 | US$1m | US$495k | -US$30m |
| Sep 30 2023 | n/a | n/a | -US$41m |
| Jun 30 2023 | n/a | n/a | -US$40m |
| Mar 31 2023 | n/a | n/a | -US$31m |
| Dec 31 2022 | US$2m | US$466k | -US$31m |
| Sep 30 2022 | n/a | n/a | -US$25m |
| Jun 30 2022 | n/a | n/a | -US$30m |
| Mar 31 2022 | n/a | n/a | -US$40m |
| Dec 31 2021 | US$2m | US$405k | -US$39m |
| Sep 30 2021 | n/a | n/a | -US$38m |
| Jun 30 2021 | n/a | n/a | -US$33m |
| Mar 31 2021 | n/a | n/a | -US$30m |
| Dec 31 2020 | US$835k | US$368k | -US$27m |
| Sep 30 2020 | n/a | n/a | -US$23m |
| Jun 30 2020 | n/a | n/a | -US$19m |
| Mar 31 2020 | n/a | n/a | -US$16m |
| Dec 31 2019 | US$629k | US$335k | -US$15m |
보상 대 시장: Sabrina의 총 보수(USD801.08K)는 US 시장에서 비슷한 규모 기업의 평균(USD627.70K) 수준입니다.
보상과 수익: Sabrina의 보상은 지난 1년 동안 회사 실적과 일치했습니다.
CEO
Sabrina Johnson (58 yo)
11yrs
재임 기간
US$801,081
보수
Ms. Sabrina Martucci Johnson serves as Director at BIOCOM, Inc. since February 2021 and serves as its Chairman since January 2025. Ms. Johnson Founded Dar? Bioscience since 2015 and serves as its Chief Exe...
리더십 팀
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| CEO, President | 11yrs | US$801.08k | 0.55% $ 227.7k | |
| Chief Accounting Officer | 4.1yrs | US$546.86k | 0% $ 0 | |
| Vice President of Operations | 11.3yrs | 데이터 없음 | 데이터 없음 | |
| Chief Scientific Officer | 7.9yrs | 데이터 없음 | 데이터 없음 | |
| Vice President of Corporate Affairs & Development | no data | 데이터 없음 | 데이터 없음 |
9.5yrs
평균 재임 기간
58yo
평균 나이
경험이 풍부한 관리: DARE의 경영진은 노련하고 경험이 풍부합니다(평균 재임 9.5 년).
이사회 구성원
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| CEO, President | 8.8yrs | US$801.08k | 0.55% $ 227.7k | |
| Independent Chairman of the Board | 12.3yrs | US$87.82k | 0.0059% $ 2.4k | |
| Member of Scientific Advisory Board | 7.2yrs | 데이터 없음 | 데이터 없음 | |
| Independent Director | 11.6yrs | US$55.82k | 0% $ 0 | |
| Independent Director | 8.8yrs | US$60.32k | 0.14% $ 58.3k | |
| Independent Director | 8.1yrs | US$59.32k | 0% $ 0 | |
| Independent Director | 7.7yrs | US$66.82k | 0.00029% $ 119.9 |
8.8yrs
평균 재임 기간
69yo
평균 나이
경험이 풍부한 이사회: DARE의 이사회는 경험이 있음으로 간주됩니다(평균 재임 8.8 년).
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/14 06:39 |
| 종가 | 2026/05/14 00:00 |
| 수익 | 2025/12/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Daré Bioscience, Inc.는 5명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Brian Kemp Dolliver | Brookline Capital Markets |
| Douglas Tsao | H.C. Wainwright & Co. |
| Jason McCarthy | Maxim Group |